Dr. Ferris on Pembrolizumab and Nivolumab in Head and Neck Cancer

Robert Ferris, MD, PhD
Published: Tuesday, Jun 27, 2017



Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with head and neck cancer.

The field has gotten to a point where pembrolizumab and nivolumab can be used interchangeably, explains Ferris.

According to Ferris, trials looking at combinations and earlier lines of therapy with chemoradiation are being investigated with both of these agents.
 
SELECTED
LANGUAGE


Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with head and neck cancer.

The field has gotten to a point where pembrolizumab and nivolumab can be used interchangeably, explains Ferris.

According to Ferris, trials looking at combinations and earlier lines of therapy with chemoradiation are being investigated with both of these agents.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x